[e-drug] WHO AMDSmail and Summary report of GPRM

["Tamura, Kenji" <tamurak@who.int>]

E-DRUG: WHO AMDSmail and Summary report of GPRM
----------------------------------------------

Dear Reader

The AIDS Medicines and Diagnostic Services (AMDS) of WHO HIV department
has published the first issue of AMDSmail, a news-brief to keep you
informed on key procurement and supply management (PSM) related
developments and activities by AMDS team and its partners organizations.
AMDSmail will be produced every 3 months. The following is the list of
topics covered in the first issue of AMDSmail
(http://www.who.int/hiv/amds/amdsmailJune.pdf)
 
- New dosage recommended by WHO for stavudine (d4T)
- Global Fund Round 7: PSM plan in health system strengthening (HSS)
- UNITAID supports price reduction of 6 second line ARVs
- Abbott lowers prices of Kaletra/Aluvia (lopinavir/ritonavir) after
discussion with Director-General of WHO
- PSM toolbox project launched
- Capacity building and training workshops on drug procurement and
supply management
- Creating a quality supply chain in Guyana for quality health care
- Breaking through barriers: Delivering essential medicines in the
developing world
- Handbook of supply management (version 1)
- A quarterly summary report from Global Price Reporting Mechanism
- WHO Prequalification Annual report 2006
 
A quarterly summary report from Global Price Reporting Mechanism  

The Global Price Reporting Mechanism (GPRM) is a web-based price
monitoring tool that captures the transaction data (price, volume,
source) of ARV drugs, to help HIV/AIDS treatment programmes in countries
to identify and compare pricing for procurement of HIV drugs. GPRM was
created and first launched by WHO/AMDS in April 2005. The latest
quarterly report compares the transaction prices of key 1st and 2nd line
ARV regiments paid in the last 3 months by low and middle income
countries to those in the previous year. It indicates that the prices of
the 1st line regimens continue to decrease and the combination of
stavudine/lamivudine/nevirapine (d4T/3TC/NVP) is now available for less
than USD 100 per person per year. while the 2nd line regimens still
remain much more expensive in both low and middle income countries.
(http://www.who.int/hiv/amds/GPRM%20summary%20April2007.pdf)

For further information please contact Kenji Tamura (amds@who.int)

Kenji Tamura MD PhD

WHO 
HIV TB and Malaria cluster/HIV department (HTM/HIV) 
AIDS Medicines and Diagnostics Services (AMDS) 
20 Avenue Appia, CH-1211 
Geneva 27 Switzerland 
********************************************* 
tamurak@who.int 
phone 22-791-1641 
fax      22-791-4887 
WHO/HTM/HIV/AMDS  
http://www.who.int//hiv/amds/en